欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

美國ChemoCentryx
ChemoCentryx公司正在開發(fā)用于治療自身免疫性疾病、炎性疾病和腫瘤的口服藥物，這些藥物主要針對趨化因子和化學(xué)誘導(dǎo)系統(tǒng)。
ChemoCentryx公司最領(lǐng)先的藥物是Traficet-EN，目前處于治療克羅恩病的Ⅲ期臨床試驗階段和乳糜瀉的Ⅱ期臨床階段以及潰瘍性結(jié)腸炎的I期臨床研究階段。另外，該公司還有一些藥物處于I期臨床階段，分別是治療胃腸道疾病的CCX025、治療脈管狹窄和多發(fā)性硬化癥的CCX140以及治療類風(fēng)濕性關(guān)節(jié)炎的CCX354。



ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.